Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Accuray Inc (ARAY)

Accuray Inc (ARAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,066
  • Shares Outstanding, K 118,783
  • Annual Sales, $ 458,510 K
  • Annual Income, $ -1,590 K
  • EBIT $ -18 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.19
  • Price/Sales 0.10
  • Price/Cash Flow 8.80
  • Price/Book 0.87
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.11 on 02/04/26
  • Next Earnings Date 04/29/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Options Overview Details

View History
  • Implied Volatility 194.62% (-396.87%)
  • Historical Volatility 85.11%
  • IV Percentile 44%
  • IV Rank 15.49%
  • IV High 1,108.47% on 03/19/26
  • IV Low 27.18% on 03/17/26
  • Expected Move (DTE 24) 0.1530 (39.79%)
  • Put/Call Vol Ratio 2.14
  • Today's Volume 132
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 7,106
  • Open Int (30-Day) 19,897
  • Expected Range 0.2315 to 0.5375

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +4,994,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3301 +16.48%
on 03/13/26
0.6220 -38.18%
on 02/26/26
-0.2086 (-35.17%)
since 02/24/26
3-Month
0.3301 +16.48%
on 03/13/26
0.9300 -58.66%
on 01/06/26
-0.4752 (-55.28%)
since 12/24/25
52-Week
0.3301 +16.48%
on 03/13/26
2.1000 -81.69%
on 10/10/25
-1.5155 (-79.76%)
since 03/24/25

Most Recent Stories

More News
Accuray: Fiscal Q2 Earnings Snapshot

Accuray: Fiscal Q2 Earnings Snapshot

ARAY : 0.3845 (+1.34%)
Accuray Reports Fiscal 2026 Second Quarter Financial Results

MADISON, Wis. , Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.

ARAY : 0.3845 (+1.34%)
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

MADISON, Wis. , Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference...

ARAY : 0.3845 (+1.34%)
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth

MADISON, Wis. , Dec. 15, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan....

ARAY : 0.3845 (+1.34%)
Accuray: Fiscal Q1 Earnings Snapshot

Accuray: Fiscal Q1 Earnings Snapshot

ARAY : 0.3845 (+1.34%)
Accuray Reports Fiscal 2026 First Quarter Financial Results

MADISON, Wis. , Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.

ARAY : 0.3845 (+1.34%)
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new...

ARAY : 0.3845 (+1.34%)
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025

MADISON, Wis. , Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference...

ARAY : 0.3845 (+1.34%)
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

Industry Veteran Steve La Neve Named Chief Executive Officer  Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor...

ARAY : 0.3845 (+1.34%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 33.82 (+0.56%)
ARAY : 0.3845 (+1.34%)
KURA : 8.07 (-3.00%)
GTBP : 0.4751 (+1.41%)
TNGX : 19.48 (+2.74%)

Business Summary

Accuray Inc. designs, develops & sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company's product suite includes the CyberKnife Systems and the TomoTherapy Systems. It primarily generates revenues by selling the CyberKnife & TomoTherapy Systems and providing...

See More

Key Turning Points

3rd Resistance Point 0.4148
2nd Resistance Point 0.4030
1st Resistance Point 0.3937
Last Price 0.3845
1st Support Level 0.3726
2nd Support Level 0.3608
3rd Support Level 0.3515

See More

52-Week High 2.1000
Fibonacci 61.8% 1.4239
Fibonacci 50% 1.2150
Fibonacci 38.2% 1.0062
Last Price 0.3845
52-Week Low 0.3301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.